Literature DB >> 11561933

The impact of antidepressant discontinuation versus antidepressant continuation on 1-year risk for relapse of bipolar depression: a retrospective chart review.

L Altshuler1, L Kiriakos, J Calcagno, R Goodman, M Gitlin, M Frye, J Mintz.   

Abstract

BACKGROUND: Current treatment guidelines recommend discontinuation of an antidepressant within 3 to 6 months after remission of depression in patients with bipolar illness. Yet few studies directly compare the impact of antidepressant discontinuation versus antidepressant continuation on the risk for depressive relapse in patients with bipolar disorder who have been successfully treated for a depressive episode.
METHOD: In a retrospective chart review, patients with DSM-IV bipolar disorder who were treated for an index episode of depression by adding antidepressant medication to ongoing mood stabilizer medications were identified. The risk of depressive relapse in 25 subjects who stopped antidepressant medications after improvement was compared with the risk of depressive relapse in 19 subjects who continued antidepressants after improvement.
RESULTS: Termination of antidepressant medication significantly increased the risk of a depressive relapse. Antidepressant continuation was not significantly associated with an increased risk of mania.
CONCLUSION: While this study may have been limited by the retrospective nature of the chart review, nonrandomized assignment of treatment, and reliance on unstructured progress notes, it suggests that antidepressant discontinuation may increase the risk of depressive relapse in some patients with bipolar disorder. Further research is needed to clarify whether maintenance antidepressant treatment may be warranted in some patients with bipolar disorder, especially in those with frequent recurrent depressive episodes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11561933     DOI: 10.4088/jcp.v62n0807

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  17 in total

Review 1.  Bipolar depression: management options.

Authors:  Gin S Malhi; Philip B Mitchell; Shahzad Salim
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 2.  New findings from the Bipolar Collaborative Network: clinical implications for therapeutics.

Authors:  Robert M Post; Lori L Altshuler; Mark A Frye; Trisha Suppes; Susan McElroy; Paul E Keck; Gabriele S Leverich; Ralph Kupka; Willem A Nolen; Heinz Grunze
Journal:  Curr Psychiatry Rep       Date:  2006-12       Impact factor: 5.285

3.  Efficacy and mood conversion rate of short-term fluoxetine monotherapy of bipolar II major depressive episode.

Authors:  Jay D Amsterdam; Justine Shults
Journal:  J Clin Psychopharmacol       Date:  2010-06       Impact factor: 3.153

Review 4.  Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry.

Authors:  Konstantinos N Fountoulakis; Siegfried Kasper; Ole Andreassen; Pierre Blier; Ahmed Okasha; Emanuel Severus; Marcio Versiani; Rajiv Tandon; Hans-Jürgen Möller; Eduard Vieta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-06       Impact factor: 5.270

Review 5.  Chronobiological Therapy for Mood Disorders.

Authors:  Sara Dallaspezia; Masahiro Suzuki; Francesco Benedetti
Journal:  Curr Psychiatry Rep       Date:  2015-12       Impact factor: 5.285

6.  Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study.

Authors:  Jay D Amsterdam; Justine Shults
Journal:  Am J Psychiatry       Date:  2010-04-01       Impact factor: 18.112

7.  Efficacy and mood conversion rate during long-term fluoxetine v. lithium monotherapy in rapid- and non-rapid-cycling bipolar II disorder.

Authors:  Jay D Amsterdam; Lola Luo; Justine Shults
Journal:  Br J Psychiatry       Date:  2012-10-25       Impact factor: 9.319

Review 8.  Do recent efficacy data on the drug treatment of acute bipolar depression support the position that drugs other than antidepressants are the treatment of choice? A conceptual review.

Authors:  Hans-Jürgen Möller; Heinz Grunze; Karl Broich
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-08-04       Impact factor: 5.270

9.  Bipolar-I depression outpatient treatment quality and costs in usual care practice.

Authors:  Alisa B Busch; Richard G Frank; Gary Sachs
Journal:  Psychopharmacol Bull       Date:  2008

Review 10.  Adjunctive use of modafinil in bipolar patients: just another stimulant or not?

Authors:  Richard C Shelton; Rakesh Reddy
Journal:  Curr Psychiatry Rep       Date:  2008-12       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.